MicroRNAs in Pulmonary Hypertension

Guofei Zhou, PhD¹, Tianji Chen, PhD¹, J Usha Raj, MD¹,²

¹Department of Pediatrics, University of Illinois at Chicago, ²Children's Hospital University of Illinois, University of Illinois Hospital and Health Sciences System, Chicago, IL, USA

*Address correspondence to: J Usha Raj, MD, Department of Pediatrics, University of Illinois at Chicago, 840 S. Wood Street, M/C 856, Ste 1206, Chicago, IL, 60612. Phone: 312-996-8352; Fax: 312-996-8204, E-mail: usharaj@uic.edu
Abstract

Pulmonary arterial hypertension (PAH) is a devastating disease without effective treatment. Despite decades of research and development of novel treatments, PAH remains a fatal disease, suggesting an urgent need for better understanding of the pathogenesis of PAH. Recent studies suggest that microRNAs (miRNAs) are dysregulated in patients with PAH and in experimental pulmonary hypertension. Furthermore, normalization of a few miRNAs is reported to inhibit experimental pulmonary hypertension. We have reviewed the current knowledge about miRNA biogenesis, miRNA expression pattern, and their roles in regulation of pulmonary artery smooth muscle cells, endothelial cells, and fibroblasts. We have also identified emerging trends in our understanding of the role of miRNAs in the pathogenesis of PAH and propose future studies that might lead to novel therapeutic strategies for the treatment of PAH.

Key words: pulmonary arterial hypertension, microRNA
Pulmonary arterial hypertension (PAH) is a fatal disease without effective treatment (1, 2). PAH can be classified into many subcategories, including idiopathic PAH (IPAH), heritable PAH (HPAH), and PAH associated with other diseases (APAH) such as connective tissue diseases (3). All types of PAH share common pathological changes, such as pulmonary artery endothelial cell (PAEC) proliferation, pulmonary artery smooth muscle cell (PASMC) proliferation, migration, and contraction, inflammation, as well as fibroblast proliferation, activation, and migration. Numerous factors contribute to the pathogenesis of PAH, including genetic, epigenetic, and environmental factors. MicroRNAs (miRNAs) are small non-coding endogenous RNA molecules consisting of approximately 21-25 nt (4, 5). A single miRNA can regulate hundreds of genes or proteins and conversely multiple miRNAs can regulate one protein (5). In this review, we have summarized recent knowledge about the role of miRNAs in the pathogenesis of PAH, particularly in the three principal cell types involved, namely, pulmonary artery smooth muscle cells (PASMC), endothelial cells (PAEC) and fibroblasts (Figure 1), and provide a perspective for needed research in this field. Although we do not include a discussion on the role of miR-126 in PAH, a recent review has summarized the data reported in the 2013 Grover Conference (6).

**MiRNA-mediated gene regulation**

The generation of mature miRNAs is a multi-step process (Figure 2). In the nucleus, miRNA genes are transcribed by RNA polymerase II or III into primary miRNA transcripts (pri-miRNA) that contain hairpin sequences. Pri-miRNAs are cleaved by the ribonuclease (RNase) III Drosha-DGCR8 (DiGeorge syndrome critical region 8) complex into precursor miRNAs (pre-miRNAs) (7, 8). Pre-miRNAs are transported to the cytoplasm by exportin 5–Ran-GTP and processed to double-stranded mature miRNAs by the RNase Dicer in complex with the double-stranded RNA-binding protein TRBP (7, 8). After the separation of the two strands by helicases, the passenger strand is degraded, whereas the functional (guide) strand of the mature miRNA is loaded with Argonaute (Ago) 2 proteins and incorporated into the RNA-induced silencing
complex (RISC). In RISC, through complementary sequences, the guide strand of miRNAs recognizes and binds to the 3'-untranslated regions (UTR) of their mRNA targets, leading to mRNA destabilization, partial mRNA degradation, and repression of protein translation (7, 8). In recent years, a non-canonical pathway of miRNA biogenesis has been reported (9, 10). Short introns with hairpin are spliced and debranched to yield mirtron hairpins, which mimic the structural features of pre-miRNAs. This process appears to be independent of Drosa-mediated cleavage. Mirtron is exported to cytoplasm by exportin-5 and processed to mature and functional miRNAs (9, 10). Although mirtrons were originally identified in flies and nematodes, a recent report suggested that there are abundant mirtrons in the human and mouse (11). The miRNA pathway is evolutionarily conserved and regulates many aspects of cellular function including cell cycle progression and cellular differentiation, proliferation, survival, and metabolism (12, 13). During evolution, sequence and expression pattern of many miRNAs are conserved throughout phylogeny and miRNA diversity correlates with speciation. Increases in miRNA numbers are generally associated with increased structural complexity over evolution time (14). To date, miRBAs has reported approximately 2000 human miRNAs in its release version 20 (http://www.mirbase.org/index.shtml). It is estimated that over 30% of human genes are regulated by miRNAs (5). Expression pattern of miRNAs are regulated by many factors, such as the developmental stage and age, gender, and environmental factors and displays spatiotemporal features. For example, expression levels of microRNA-17~92 (miR-17~92) are high in embryonic stem cells and mid-gestation embryos and relatively low in mature tissues and during aging (15, 16). The miR-17-92 cluster is also highly expressed during T-cell activation and silenced during memory development (17). In the lung, a group of miRNAs are differentially expressed between males and females, presumably by retinoin, IGFR1, Tp53 and Akt pathways (18). Hypoxia is known to alter the expression of a number of miRNAs(19). Therefore, miRNAs may be important effectors in regulation of gene expression with respect to
development and aging, sex differences, response to exogenous environmental influences and human diseases.

Within an organism there are multiple organs/tissues/cells that exhibit organ/tissue/cell specific gene expression signatures. Since miRNAs regulate multiple mRNA targets, it is reasonable to speculate that expression of miRNAs is also organ/tissue/cell specific. Landgraf and colleagues reported the sequences of over 250 small RNA libraries from 26 different organ systems and cell types and reported a cell/tissue specific miRNA expression pattern in mammals. They found that more than 97% of all miRNAs originated from less than 300 miRNAs, suggesting a ubiquitous expression of abundant miRNAs, such as miR-16 and miR-21 (20). Although very few miRNA were exclusively expressed in given tissues/cells, a third of miRNAs demonstrate a certain degree of tissue specificity (e.g., miR-224 in respiratory system; miR-142, miR-144, miR-150, miR-155, and miR-223 in hematopoietic cells) (20). More importantly, the expression levels of miRNAs inversely correlate with their predicted mRNA targets in a given tissue as reported by Sood et al (21). Intriguingly, there are exceptions: expression of miR-124, miR-133, and miR-206 parallels the expression of their predicted targets in the developing central nervous system and a few targets are expressed at even higher levels in the presence of their upstream miRNAs (22). This miRNA-mRNA co-expression phenomenon may suggest a possible negative feedback response, indicating a complex regulatory circuit between miRNA and mRNA (22, 23).

Under pathological conditions such as cancer, miRNA expression is dysregulated. MiR-17-5p, miR-19a/b, miR-18a/b, and miR-25 are generally upregulated in cancer, while other miRNAs display a cancer type-specific pattern (e.g., miR-181a-1(4) was absent from B-cell chronic lymphocytic leukemia; miR-126 was highly expressed in precursor B-cell acute lymphoblastic leukemia; levels of miR-150 was reduced in Burkitt’s and diffuse large B-cell lymphoma) (20).
Dysregulation of miRNA in PH

There are reports that the expression profile of miRNAs in human lungs with PAH is altered compared to normal controls. Courboulin and colleagues compared 337 miRNAs between PAH and control lungs and identified 6 miRNAs that were upregulated and only one miRNA, miR-204, that was downregulated in PAH (24). Rhodes et al. performed a microarray screen on plasma miRNAs from eight patients with PAH and eight healthy control subjects and identified fifty-eight miRNAs that were dysregulated, with plasma miR-150 levels being reduced most significantly in PAH patients (25). Other studies have indicated that miR-17~92, miR-143/145, miR-21, as well as many other miRNAs are dysregulated in PAH (24, 26-33), however, only a handful of these miRNAs has been confirmed to play a role in PAH using a variety of experimental models of PH (Table 1). MiR-17~92, miR-143/145, miR-21, and miR-124 have been extensively studied and hundreds of targets identified, whereas miR-204, miR-424, and miR-503 are less studied. We have listed the functional targets of these miRNAs in Table 2.

Caruso et al. utilized models of PH induced by hypoxia and monocrotaline (MCT) in rats and found that chronic hypoxia reduced the expression of Dicer, suggesting an overall downregulation of miRNAs in PAH (29). Subsequently, miR-204 was shown to be downregulated in hypoxia- and MCT-induced PH (24). Although some miRNAs are consistently upregulated (miR-322 and miR-451) or downregulated (miR-22, miR-30, and let-7f) in both hypoxia and monocrotaline-induced PH, there are also some significant differences in the miRNA expression profiles between these two models (29).

A more definite causative role for miRNAs in the pathogenesis of PAH is supported by studies where inhibition of miR-21, miR-145, or miR-17 and miR-20a of the miR-17~92 cluster prevents or reverses existing PAH (26, 31, 34-36). Altered expression of miRNAs is also associated with plexiform vasculopathy with severe PAH (37). Expression levels of miR-143/145 and miR-204
are higher in concentric (CLs) than in plexiform (PLs) lesions, whereas miR-126 and miR-21 are higher in PLs than in CLs (37), suggesting a potential role for miRNAs as diagnostic or prognostic markers in PAH.

Careful assessment of the role of miRNAs in the pathogenesis of PAH requires accurate and reliable methods to detect and measure levels of miRNAs. Generally, levels of miRNAs can be measured by microarray analysis, deep-sequencing, real-time PCR, Northern blot analysis, and In-Situ hybridization (38). Microarray analysis can simultaneously measure a large number of miRNAs and is most often used to obtain the global miRNA expression pattern as a prelude to subsequent validation by other techniques, such as real-time PCR. Deep sequencing generates massive small RNA sequences from a given sample and measures absolute abundance of given miRNAs, and thus contains an advantage over microarray analysis to detect miRNAs with low copy numbers. Hence deep sequencing is a powerful tool to identify novel miRNAs. Although Northern blotting is time consuming and suffers from low sensitivity, it is useful to visualize mature miRNAs and pre-miRNAs. Since miRNA expression is tissue- or cell-specific and many of them play a tissue specific role in PAH as discussed in this review, measuring miRNA levels in a tissue- or cell specific manner is useful, especially when combined with In-Situ hybridization. However, given the small size of target miRNA sequences, In-Situ hybridization may have low specificity and therefore is technically challenging to gain accurate results. Quantitative Real-time PCR (qPCR) is by far the most popular method to measure miRNA levels and can be carried out by SYBR green or Taqman probes. Two common methods were developed to synthesize cDNAs from miRNAs: the poly(A) method, in which miRNAs are polyadenylated by poly(A) polymerase, followed by cDNA synthesis with a universal oligo(dT) primer, and the stem-loop method, in which stem-loop primers are used for the cDNA synthesis. The poly(A) method is suitable for high-throughput profiling of miRNA expression, yet it is less specific due to cDNA synthesis of all polyadenylated RNAs including mRNA, rRNA, tRNA, pri-,
pre- and mature miRNAs and a universal reverse primer. Stem-loop RT primers are specific for an individual miRNA, but the efficiency of the stem-loop method is relatively low and costly. Kang and colleagues reported a modified qPCR assay for miRNA quantification, namely the S-Poly(T) miRNA assay. In this method, miRNAs are polyadenylated and cDNAs are synthesized with a S-Poly(T) primer. cDNAs are then amplified by a universal reverse primer, a universal Taqman probe, and a miRNA specific forward primer containing an oligo(dT)$_{11}$ sequence and six miRNA-specific bases. This method is reported to have a 4-fold increase in sensitivity compared to traditional methods (39).

**MiRNA regulation of PASMC phenotype**

The miR-17~92 cluster. The miR-17~92 cluster contains 6 mature miRNAs (mi-17, miR-18a, miR-19a, miR-19b, miR-20a, and miR-92a) that are transcribed as one common primary miRNA until it is processed to mature miRNAs (40). Although miR-17~92 is known to be oncogenic, recent studies suggest that miR-17~92 also plays an important role in lung development and in the pathogenesis of PAH (15, 27, 28, 41). Loss of miR-17~92 leads to severe hypoplastic lungs in mouse embryos and these mice die shortly after birth (15). MiR-17~92 induces proliferation of lung epithelial cells and inhibits differentiation of lung epithelial progenitor cells (15). We have reported that miR-17~92 is down-regulated in PASMC isolated from PAH patients (27, 28). We found that reduced expression of miR-17~92 in PAH patients is associated with decreased levels of α-smooth muscle actin (α-SMA), SM22α, and Calponin, suggesting a correlation between a de-differentiated smooth muscle cell phenotype and loss of miR-17~92 expression. Conversely, overexpression of miR-17~92 restores the differentiated phenotype. Our results also showed that miR-17~92 binds to the 3′-UTR region of PDZ and LIM domain protein 5 (PDLIM5) and inhibits its expression. Furthermore, PDLIM5 is essential for miR-17~92-mediated TGF-β/SMAD signaling and PASMC phenotype (27, 28). Interestingly, Pullamsetti et al. reported that in the hypoxia-induced PH mouse model, miR-17 is transiently upregulated.
Inhibition of miR-17 prevented and partially reversed hypoxia-induced PH, presumably by inducing p21 to inhibit proliferation of PASMC (26). Therefore, miR-17~92 appears to contribute to PAH by two mechanisms: 1) in the initial stage of remodeling of blood vessels, upregulation of miR-17~92 promotes PASMC proliferation; 2) in the later progression stage, reduced miR-17~92 increases PDLIM5 to maintain PASMC in a de-differentiated state.

**MicroRNA-21.** In normal human PASMC, hypoxia induces miR-21 by three fold with a decrease in expression of miR-21 targets such as programmed cell death protein 4 (PDCD4), Sprouty 2 (SPRY2), and peroxisome proliferator-activated receptor-α (PPARα). Treatment with anti-miR-21 inhibits hypoxia-induced PASMC proliferation and migration and increases the expression of its target proteins (42). Inhibition of miR-21 prevents and reverses hypoxia-induced PAH (36). Thus, elevated levels of miR-21 may contribute to PASMC proliferation and migration and development of PAH (42).

**MicroRNA-124.** The nuclear factor of activated T cells (NFAT) signaling pathway has been implicated in PASMC proliferation and PAH. Kang and colleagues adopted a systematic approach to identify miRNAs that regulate the NFAT pathway using a luciferase reporter. Among eight unique miRNAs that modulate NFAT activity, miR-124 exhibits a robust inhibition of NFAT activity, dephosphorylation, nuclear translocation, and inhibition of NFAT-dependent transcription of IL-2. MiR-124 appears to directly target NFATc1, CAMTA1 (calmodulin-binding transcription activator 1), and PTBP1 (polypyrimidine tract-binding protein 1) to modulate NFAT pathway. During hypoxia, miR-124 is down-regulated in human PASMC and mouse lungs. Overexpression of miR-124 inhibits human PASMC proliferation. The anti-proliferative effects of miR-124 may be useful in developing treatments for PAH (43).
The miR-143/145 cluster. MiR-143 and miR-145 are organized in a polycistronic cluster and are controlled by a common promoter region and transcribed as one common primary miRNA (44). MiR-143/145 cluster locates within a 1.7 kb highly conserved region of mouse chromosome 18 (45) or human chromosome 5q33 (46). Since miR-143/145 is most abundantly expressed in heart, vascular and visceral SMC, it has been labeled as a SMC specific miRNA (47, 48). A few downstream targets of miR-143 and miR-145 have been identified and miR-143/145 has been shown to be necessary for maintenance of the contractile phenotype of SMC and for its fate (44, 49). For example, in rat aorta vascular SMC, miR-145 inhibits KLF5, resulting in induction of myocardin and increased expression of SMC markers such as α-SMA, calponin and SM-MHC (48). Overexpression of miR-145 prevents cell growth in vitro (48). Another study suggests that miR-143 (by inhibiting Elk-1) and miR-145 (by inhibiting KLF4 and CamKII-δ) inhibit SMC proliferation but promote differentiation (44). MiR-143/145 expression is upregulated in human PAH and hypoxia-induced mouse PH (24, 31). Interestingly, PAH patients that have bone morphogenetic protein receptor type II (BMPR2) mutations have increased miR-145 levels. Downregulation of BMPR2 also induces miR-145 in human and mouse PASMC, suggesting that miR-145 is a downstream target of BMP signaling. Indeed, Davis-Dusenbery et al. discovered that in vascular smooth muscle cells (VSMCs) TGF-β and BMP4 induce myocardin (Myocd) expression or nuclear translocation of Myocd-related transcription factors (MRTFs), respectively, resulting in increased transcription of pri-miR-143/145 and higher levels of mature miR-143 or miR-145, repression of KLF4 expression, and increased contractile gene expression (50). In addition, although manipulation of miR-145 does not appear to alter baseline pulmonary vascular function, anti-miR-145 but not anti-miR-143 inhibits hypoxia-induced PH in mice (31).

MiR-204. MiR-204 locates within the intronic region of TRPM3 (transient receptor potential melastatin 3), shares the same regulatory mechanism as TRPM3 and is downregulated by
STAT3 (24, 51). miR-204 is primarily expressed in PASMC and its expression levels are reduced in human PAH and in hypoxia- and MCT-induced PH in rats. Pro-hypertensive signaling molecules, such as PDGF, endothelin-1 and angiotension II decrease miR-204 expression and reduction of miR-204 activates Src-STAT3-NFAT pathway via upregulation of SHP2 (Src activators), leading to PASMC proliferation and increased resistance to apoptosis. MiR-204 mimics can reverse MCT-induced PH (24). miR-204 levels appear to be negatively correlated with the severity of human PAH and the amount of miR-204 in buffy coat cells mirrors the levels in PASMC. Interestingly, Lee et al. reported that mesenchymal stromal cell-derived exosomes but not fibroblast-derived exosomes increase lung levels of miR-204, suppress STAT3 signaling induced by hypoxia, and inhibit vascular remodeling and hypoxic pulmonary hypertension (52). These studies suggest that miR-204 might be used as a diagnostic marker for PAH and it may be a potential candidate in the treatment of this disease (24, 52).

**MiR-210.** miR-210 is consistently and reproducibly induced by hypoxia in various cell types (53). miR-210 is robustly induced by hypoxia in PASMC and mouse lungs via an HIF-1 dependent pathway. Upregulation of miR-210 suppresses E2F3 and increases resistance to apoptosis, resulting in hyperplasia of PASMC (54).

**MiRNA regulation of pulmonary artery endothelial homeostasis in PAH**

**The miR-17~92 cluster.** MiR-17, miR-18, miR-19 and miR-20 expression is increased upon the induction of endothelial cell differentiation of murine embryonic stem cells or induction of pluripotent stem cells. In contrast, miR-92a and the primary miR-17-92 transcript were downregulated, suggesting that miR-17~92 may be involved in angiogenesis (55). In endothelial cells, VEGF induces miR-17~92 expression and miR-17-92 is required for endothelial cell proliferation and angiogenesis (56). A fraction of PAH patients have mutations of BMPR2 and downregulation of BMPR2 is associated with PAH (57). Brock et al. have discovered that miR-
17-5p and miR-20a, two members of the miR-17~92 cluster, directly target BMPR2 in pulmonary artery endothelial cells (PAEC). They showed that interleukin (IL)-6, a pro-hypertensive cytokine, upregulates miR-17/92 expression via STAT3 (signal transducer and activator of transcription 3). The promoter region of the miR-17/92 gene (C13orf25) contains a highly conserved STAT3-binding site and persistent activation of STAT3 induces miR-17~92 (58). These results suggest that inhibition of BMPR2 results in upregulation of miR-17~92 which increases PAEC proliferation and makes them resistant to apoptosis, resulting in PH (Figure 3).

**MiR-21.** Although multiple factors contribute to the pathogenesis in PAH, it is not clear how these multiple pathways are interlinked. Parikh and colleagues adopted a network bioinformatics approach to identify miR-21 as a key miRNA controlling multiple functional pathways associated with hypoxia, inflammation, and genetic haplo-insufficiency of BMPR2. First, they compiled a list of 131 genes that are implicated in the development of PH and constructed a consolidated interactome and mapped the interactions among these genes. Then they used TargetScan 5 algorithm to predict the miRNAs that regulate these genes. Out of a select group of 29 miRNAs predicted to control expression of a convergent set of pathways in PH, they chose to study miR-21 and found that miR-21 is upregulated in pulmonary tissue from several rodent models of PH and patients with PAH. Both hypoxia and BMPR2 signaling upregulate miR-21 in cultured PAEC, whereas miR-21 downregulates BMPR2 expression, forming a negative feedback loop. MiR-21 directly targets and suppresses RhoB expression and Rho-kinase activity, resulting in decreased angiogenesis and vasodilatation. Loss of miR-21 increases RhoB expression and Rho-kinase activity, exaggerating hypoxia/SU5416-induced PH (34). A recent study reported that deletion of miR-21 in mice results in activation of the PDCD4/caspase-3 axis in PAEC, and induces progressive PH. Conversely, overexpression of miR-21 reduces PDCD4 expression and protects mice from PH in the hypoxia/SU5416 model (59). Thus, miR-21 appears to act as a brake to inhibit the progression of PH. However, other
studies suggest that miR-21 is downregulated in MCT induced rat PH and in endothelial cells of human PAH (29, 30) and inhibition of miR-21 prevents and reverses hypoxia-induced PH (36). Sarkar and colleagues showed a three-fold up-regulation of miR-21 in hypoxic human PASMC, however, Caruso et al. did not find any change in miR-21 expression in hypoxic rat lungs or rat PASMCs, suggesting a differential regulation of miR-21 between two species (29, 42). Caruso and colleagues also reported that miR-21 is downregulated in rat lungs of MCT-induced PH but not in hypoxia-induced PH, whereas Parikh and colleagues showed that miR-21 is induced in MCT treated rats in a time dependent manner (29, 34). It is unknown whether this discrepancy is due to the different dose of MCT (60 mg/kg in the latter study; unspecified in the former study) or the different normalization methods during miR-21 measurement (miR-21 expression is normalized to U87 in the former study and Rnu48 in the latter study). The anti-PH role of miR-21 is demonstrated in the hypoxia/SU5416 model (34, 59), while the pro-PH role of miR-21 is shown in hypoxia alone model (36). This contradiction may be partially explained by the difference in PH severity and histopathological changes between hypoxia/SU5416- and hypoxia-induced PH. The hypoxia/SU5416 PH model is characterized by exacerbated PAEC proliferation, which more closely mimics human PAH. In PAEC, miR-21 directly suppresses RhoB expression and Rho-kinase activity and the PDCD4/caspase-3 axis, resulting in inhibition of PH (34, 59). However, in the hypoxic PH model, the PAEC proliferation is minimal and PASMC proliferation is relatively dominant. Therefore, inhibition of miR-21 prevents PASMC proliferation and migration, resulting in inhibition of PH (36). These seemingly contradicting conclusions may result from the different roles of miR-21 in the various cell types that participate in the pathogenesis of PAH. Thus, the role of miR-21 in PAH is complex and further studies are warranted to fully elucidate the involvement of miR-21 in PAH in a spatial and temporal manner.

MiR-27a. In PAEC, hypoxia induces miR-27a to increase cell proliferation and expression of ET-1 and to decrease peroxisome proliferator-activated receptor gamma (PPARγ) levels (60).
Inhibition of miR-27a prevents hypoxia-induced PAEC proliferation and endothelin 1 (ET-1) expression. More importantly, rosiglitazone (RSG), a PPARγ ligand, attenuates hypoxia-induced miR-27a, whereas miR-27a levels are upregulated in PPARγ knockout mice. These results suggest that a negative feedback loop between miR-27a and PPARγ may provide an amplifying signal to promote PH (60). However, another study showed that in PAEC and PASMC from heritable PAH (HPAH) patients, knockdown of BMPR2, a mutation responsible for Heritable PAH (HPAH), decreased BMP2-induced miR-27a expression and that miR-27a exhibits anti-proliferative effects (30). In their model, induction of miR-27a appears to signal growth suppression that is lost in HPAH (30).

**MiR-424 and miR-503.** The apelin (APLN)-apelin receptor (APLNR) signaling axis is known to maintain pulmonary vascular homeostasis (61). In PAH patients, reduction of APLN causes hyperproliferative and antiapoptotic phenotype of PAEC. APLN knockout exacerbates hypoxia-induced PH (61). Further studies suggest that persistent low levels of APLN-APLNR axis lead to reduced levels of miR-424 and miR-503, which directly suppress FGF2 and FGFR1. In PAH, downregulation of miR-424 and miR-503 induces FGF2 and FGFR1 and subsequent proliferation of PAEC and PASMC. Accordingly, restoration of miR-424 and miR-503 attenuates MCT- and hypoxia/Sugen 5416-induced PH (62). FGF2 is overexpressed in PAEC of IPAH patients and elevated levels of FGF2 contribute to PAH by both autocrine and paracrine mechanisms: in IPAH PAEC, elevated levels of FGF2 induce PAEC proliferation and resistance to apoptosis whereas suppression of FGF2 decreases PAEC proliferation and resistance to apoptosis. In PASMC, elevated secretion of FGF2 induces PASMC proliferation (63). Together, these results suggest a critical role for the APLN-miR-424/503-FGF2 pathway in the pathogenesis of PAH and miR-424 and miR-503 are negative regulators of PAH.
miRNAs that regulate fibroblasts in PAH

**MiR-124.** In PAH, remodeling of adventitia is associated with activation of adventitial fibroblasts, leading to increased cell proliferation, migration, and secretion of inflammatory cytokines. A recent report indicated that levels of miR-124 are reduced in fibroblasts isolated from PAH patients and experimental PH models (64). Reduced miR-124 causes hyperproliferation and migration of fibroblasts, whereas overexpression of miR-124 inhibits proliferation and migration of fibroblasts (64). MiR-124 can directly suppress expression of monocyte chemotactic protein-1 and polypyrimidine tract-binding protein 1, which regulate Notch1/phosphatase and tensin homolog/FOXO3/p21Cip1 and p27Kip1 signaling and fibroblast proliferation and migration (64). In addition, miR-124 appears to be suppressed by histone deacetylases and treatment of histone deacetylase inhibitors restores miR-124 expression and suppresses fibroblast proliferation, suggesting a potential therapeutic role for histone deacetylase inhibitors in PAH (64).

Although in this review we focus on the contributions of PASMC, PAEC, and fibroblasts in the pathogenesis of PAH, other reports provide compelling evidence that inflammatory cells are also critical in PAH (65, 66). Pericytes are mainly located on the external surface of small blood vessels with elongated and multibranched morphology and have been known to regulate vascular development and remodeling (67). In a subset of patients with Adams-Oliver syndrome at high risk for PH, abnormal pericyte recruitment contributes to pathogenesis of PH (68). Recently, Ricard and colleagues demonstrated that pericyte coverage is increased in PH and serves as a source of smooth muscle–like cells (69). More importantly, different cell types may communicate with each other in the pathogenesis of PAH. Hegenreider et al. reported that in endothelial cells Krüppel-like factor 2 (KLF2) binds to the promoter of the miR-143/145 cluster and upregulates the expression levels of miR-143/145. KLF2-transduced or shear-stress-
stimulated Human Umbilical Vein Endothelial Cells (HUVECs) secrete extracellular vesicles enriched with miR-143/145, which control SMC marker expression in co-cultured SMC (70). This important finding suggests a complexity in miRNA regulation and points to a potential strategy of using a miRNA- or extracellular-vesicle-mediated mechanism to treat PAH.

Future directions

**Regulation of miRNAs in PAH.** Although evidence of participation of miRNAs in PAH is emerging, the regulation of miRNAs in PAH is less known. Brock et al. found that interleukin (IL)-6, a cytokine involved in the pathogenesis of pulmonary hypertension, induces miR-17~92 via STAT3 (signal transducer and activator of transcription 3) mediated transcription and represses protein expression of BMPR2. This study provides a mechanistic explanation for the loss of BMPR2 in the development of pulmonary hypertension (58). Recent studies suggest that miR-17~92 can be regulated by c-Myc and E2F1 (71, 72), however, the implication of this in regulation of PAH remains unknown. miR-143 or miR-145 are induced by TGF-β/Myocd and BMP4/MRTF pathways (50). Davis and colleagues reported a unique mechanism by which TGF-beta and BMP signaling induces miR-21. They found that TGF-beta and BMP signaling recruits SMAD to pri-miR-21 in a complex with the RNA helicase p68 (also known as DDX5), a component of the DROSHA microprocessor complex, promoting the processing of pri-miR-21 into pre-miR-21 (73). However, the implication of this mechanism in PAH is unclear and we need to continue to study the molecular and pathobiological significance of altered miRNA expression in PAH. Given that multiple miRNAs are down- or upregulated during PAH, it is also important to investigate the crosstalk among these miRNAs.
**Identification of miRNA targets.** Several bioinformatics tools have been developed to predict the potential targets of individual miRNAs (74) and many targets have been confirmed, indicating the usefulness of these tools. However, there is increasing evidence that these tools are far from perfect in accurately predicting the targets, indicating an urgent need to find better ways to identify and confirm miRNA targets. Kang and colleagues reported a novel approach to indentifying new targets of miR-21. They overexpressed biotinylated miR-21 mimic in PASMC, recovered miR-21-bound mRNAs by the streptavidin-coated magnetic beads pulldown assay, and identified miR-21 targets by Affymetrix microarray analysis. Using this approach, they not only re-validated the previously validated miR-12 targets such as PDCD4, TGFBR2, PTEN, BMPR2, etc., but also identified nearly all members of the dedicator of cytokinesis (DOCK) 180-related protein superfamily as targets of miR-21. Interestingly, DOCK family genes are not predicted as targets of miR-21 by conventional target prediction algorithms; instead miR-21 regulates DOCK genes by base pairing at sites other than the seed sequence. Thus, this approach may serve as a powerful tool to identifying canonical and non-canonical miRNA targets (75). Since many cell types function differently, it is conceivable that miRNA targets may be cell specific or context specific, which may explain recent controversies in the role of miR-17~92 in angiogenesis (56, 76). Thus, efforts need to be made to identify and confirm targets in a context-specific manner, which may help understand biological functions of miRNAs.

**Circulating microRNAs as PAH biomarkers.** Recent reports suggest that extracellular miRNAs associate with protein complexes and are protected from RNase digestion, therefore they are stable and abundant in the circulation and can be readily detected. These observations raise the possibility that dysregulated miRNAs may serve as biomarkers for PAH diagnosis or early detection. Indeed, Rhodes et al. reported in a pilot study that circulating miR-150 is reduced in peripheral blood of PAH patients and reduced levels of miR-150 correlates with poor survival in PAH patients (25). Schlosser and colleagues reported that circulating miR-26a is
reduced in both rats with MCT-induced PH and in human with IPAH and that the levels of miR-26a positively correlate with the 6 minute walk distance (77). More importantly, the expression levels of miR-26a were specifically reduced in lungs of MCT-induced PH rats but not in the hearts and lower levels of miR-26a correlated with increased right ventricular systolic pressure (RVSP) and right ventricular (RV) hypertrophy (77), indicating that the change in levels of circulating miRNAs specifically reflects changes in diseased organs or tissues. This fact will likely increase of the use of miRNAs as PAH biomarkers.

**miRNA mimics/antagonists as therapeutic agents.** Given the success of miRNA mimics/antagonists in prevention/inhibition of experimental PH, it is reasonable to speculate that miRNA mimics/antagonists may be novel therapeutic agents for the treatment of PAH in humans. An inherent advantage of using miRNA target drugs is the ability of miRNAs to target multiple genes within a network making them more efficient. Many strategies have been developed for miRNA-based therapeutics, including antisense oligonucleotides, locked nucleic acid (LNA) antimiR, miRNA sponges, antagonirs and miR mimics, miRNA expression vectors, and miR-Mask (8, 78). The miR-122 inhibitor miravirsen (Santaris Pharma A/S) based on LNA Drug Platform was the first miRNA targeted drug to be used in a human clinical trial (79). A recent phase II study was done evaluating the safety and efficacy of miravirsen in 36 patients with chronic Hepatitis C Virus (HCV) genotype 1 infection. Miravirsen reduced HCV RNA levels in a dose-dependent manner and the effect lasted even beyond the duration of active therapy without evidence of viral resistance (ClinicalTrials.gov number, NCT01200420) (80). Currently there are seven clinical trials that are listed as active or completed in ClinicalTrials.gov (search on July 30, 2014), evaluating miR-122 and the clinical course of HCV, safety, dosing, effects on interferon-alpha null responders, and drug interactions with Telaprevir. In the lung, a search with “microRNA and lung” retrieved 23 studies and three of them are in PAH: Study NCT00806312 is to evaluate the miRNA profile and markers of inflammation in patients with
PAH; NCT02102672 is to evaluate Right Ventricular Function, Ventricular Remodeling and miRNA Profiling in PAH after administration of a Fatty Acid Oxidation Inhibitor Trimetazidine; NCT01839110 is to investigate whether ranolazine can improve the outcome of patients with stable pulmonary hypertension, on some specific therapies but with right ventricular dysfunction (RVEF ≤ 40%), accompanied by a baseline comparison of the metabolic profiling/microRNA/iPS cells of subjects with and without right ventricular dysfunction.

MiRNAs are an attractive new class of drug that have a high therapeutic potential because of their small size, known and conserved sequence and some pre-clinical evidence of their role in human diseases. However, synthetic miRNA mimics or antagonists suffer from similar drawbacks as do RNAi drugs, such as off-target effects, inefficient drug delivery, and low drug efficacy. Off-target effects of miRNAs mainly arise from three reasons: 1) lack of target specificity due to the short seed sequence; 2) the existence of multiple (even hundreds) targets for a single miRNA; 3) toxicity from miRNA-induced immune responses. Most miRNA agents are designed to be perfectly complementary to their targets and generally unable to distinguish between miRNAs within the same family or those with identical seed sequences. miR-17~92 cluster is known to be upregulated in many cancers, suggesting a potential cancer therapeutic target; however, miR-17~92 is required for lung development and homeostasis and global knockout of miR-17~92 results in severe hypoplastic lungs in embryos and these mice die shortly after birth (15), limiting the applicability of miR-17~92 as a drug target. MiRNA agents can be detected by both the innate (nucleotide sequence) and adaptive (carrier and/or nucleotide) mammalian immune systems, causing off-target toxicity (81). Another off-target effect may be caused by the overexpression of miRNA drugs, which may saturate the miRNA biogenesis machinery, altering the expression of other non-targeted miRNAs (81, 82). Many approaches have been developed to limit these off-target effects. To overcome the limitations of targeting mature miRNAs, one strategy may be to target pri-miRNAs and pre-miRNAs.
Morpholinos has been shown to inhibit miR-375 by blocking the processing of its pri-miRNAs or the pre-miRNAs, causing defective morphology of pancreatic islet cells. This phenotype has been observed with multiple precursor-targeting morpholinos (83). Targeted delivery of miRNA drugs may also limit unwanted effects. 3’-conjugation with cholesterol increased the inhibitory efficiency of the miR-122 antagomir in several tissues, particularly in liver (84). Nanoparticle and antibody-based methods are attractive cell- or tissue specific miRNA drug delivery systems (81). Hornung et al. found that immune activation is mediated by the nine nucleotides in the 3’ end of the sense strand of siRNA (equivalent to the anti-miR antisense strand (85). Notably, LNA modification of the 2’ position of the sugar ring largely reduces the immunostimulatory effects of siRNAs (86). These data provide valuable insight for the design of anti-miR oligonucleotides with minimized immunostimulatory effects. Despite progress in miRNA drug discovery, finding clinically effective miRNA drugs remains a challenge and further work is warranted.
ACKNOWLEDGEMENTS

This study was partly supported by grants from NIH HL075187 and HL110829 (J. Usha Raj), a Pulmonary Hypertension Association/Pfizer Proof-of-Concept award (in which American Thoracic Society provides administrative support), and a Gilead Sciences Research Scholars Program in Pulmonary Arterial Hypertension award (Guofei Zhou). We also thank Dr. Viswanathan Natarajan for his careful reading of our manuscript.
Table 1. A list of dysregulated microRNAs in pulmonary hypertension.

<table>
<thead>
<tr>
<th>microRNA</th>
<th>Changes in PH</th>
<th>Sample type</th>
<th>Targets</th>
<th>Function</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-17~92</td>
<td>↓</td>
<td>Human PAH PASMC</td>
<td>PDLIM5</td>
<td>PASMC differentiation</td>
<td>(27, 28)</td>
</tr>
<tr>
<td></td>
<td>Transient ↑</td>
<td>Hypoxic PH mouse lung homogenates</td>
<td>p21</td>
<td>PASMC proliferation</td>
<td>(26)</td>
</tr>
<tr>
<td>NA</td>
<td>Human PAEC</td>
<td>BMPR2</td>
<td></td>
<td>PAEC proliferation</td>
<td>(58)</td>
</tr>
<tr>
<td>miR-145</td>
<td>↑</td>
<td>Human HPAH and IPAH lung tissue and PASMC</td>
<td>KLF4, Smad4, Samd5</td>
<td>PASMC differentiation and inhibition of PASMC proliferation</td>
<td>(31)</td>
</tr>
<tr>
<td></td>
<td>Hypoxic PH mouse PASMC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BMPR2 mutation PAH PASMC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-21</td>
<td>↑</td>
<td>Hypoxic human PASMC</td>
<td>PDCD4, SPRY2, PPARα</td>
<td>PASMC proliferation</td>
<td>(42)</td>
</tr>
<tr>
<td></td>
<td>↑</td>
<td>Human pulmonary vessels (&lt;200 μm)</td>
<td>RhoB</td>
<td>Decrease angiogenesis and vasodilatation</td>
<td>(34)</td>
</tr>
<tr>
<td></td>
<td>MCT-PH rat lung homogenates</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypoxia/SU5416 mouse lung homogenates</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IL-6 transgenic PH mouse lung homogenates</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NA</td>
<td>PAEC</td>
<td>PDCD4/caspase-3</td>
<td></td>
<td>anti-apoptosis in PAEC</td>
<td>(59)</td>
</tr>
<tr>
<td>miR-204</td>
<td>↓</td>
<td>human PAH PASMC</td>
<td>SHP2</td>
<td>Apoptosis and inhibition of PASMC proliferation</td>
<td>(24)</td>
</tr>
<tr>
<td></td>
<td>human PAH lung biopsies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypoxic PH mouse lung homogenates</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MCT-PH rat lung homogenates</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-424/miR-503</td>
<td>↓</td>
<td>Human PAH PAEC</td>
<td>FGF2/FGFR1</td>
<td>Anti-proliferative and pro-apoptosis</td>
<td>(62)</td>
</tr>
<tr>
<td>No change</td>
<td>Human PAH PASMC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-124</td>
<td>↓</td>
<td>Human PAH fibroblasts</td>
<td>monocyte chemotactic protein-1 and polypyrimidine tract-binding protein 1</td>
<td>Anti-proliferative</td>
<td>(64)</td>
</tr>
</tbody>
</table>

*NA: not available*
Table 2. Other functional targets of lesser known miRNAs that participates in the development of pulmonary hypertension

<table>
<thead>
<tr>
<th>microRNA</th>
<th>Targets</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-204</td>
<td>RUNX2</td>
<td>(6, 87, 88)</td>
</tr>
<tr>
<td></td>
<td>SOX4</td>
<td>(89, 90)</td>
</tr>
<tr>
<td></td>
<td>angioptoin-1</td>
<td>(91)</td>
</tr>
<tr>
<td></td>
<td>Cdc42</td>
<td>(92)</td>
</tr>
<tr>
<td></td>
<td>TrkB</td>
<td>(93, 94)</td>
</tr>
<tr>
<td></td>
<td>Slug</td>
<td>(95)</td>
</tr>
<tr>
<td></td>
<td>Mcl-1</td>
<td>(96)</td>
</tr>
<tr>
<td></td>
<td>MAFA</td>
<td>(97)</td>
</tr>
<tr>
<td></td>
<td>SIRT1</td>
<td>(98)</td>
</tr>
<tr>
<td></td>
<td>Sox11</td>
<td>(99)</td>
</tr>
<tr>
<td></td>
<td>BDNF</td>
<td>(100)</td>
</tr>
<tr>
<td></td>
<td>SMAD4</td>
<td>(101)</td>
</tr>
<tr>
<td></td>
<td>Bcl-2</td>
<td>(94, 102)</td>
</tr>
<tr>
<td></td>
<td>LC3B</td>
<td>(103, 104)</td>
</tr>
<tr>
<td></td>
<td>TGF-betaR2 and SNAIL2</td>
<td>(51)</td>
</tr>
<tr>
<td></td>
<td>AP1S2, Bcl2i2, BIRC2, EDEM1, EZR, FZD1, M6PR, RAB22A, RAB40B, SERP1, TCF12, and TCF4</td>
<td>(105)</td>
</tr>
<tr>
<td></td>
<td>Meis2</td>
<td>(106)</td>
</tr>
<tr>
<td>miR-424 and miR-503</td>
<td>BCL-2, IGF1R</td>
<td>(107)</td>
</tr>
<tr>
<td></td>
<td>Rictor</td>
<td>(108)</td>
</tr>
<tr>
<td></td>
<td>cdc25A</td>
<td>(109, 110)</td>
</tr>
<tr>
<td>miR-424</td>
<td>PDCD4</td>
<td>(111)</td>
</tr>
<tr>
<td></td>
<td>c-Myb</td>
<td>(112)</td>
</tr>
<tr>
<td></td>
<td>VEGF, KDR</td>
<td>(113)</td>
</tr>
<tr>
<td></td>
<td>FGFR1</td>
<td>(114)</td>
</tr>
<tr>
<td></td>
<td>CDX2</td>
<td>(115)</td>
</tr>
<tr>
<td></td>
<td>CX3CL1</td>
<td>(116)</td>
</tr>
<tr>
<td></td>
<td>cyclin D1</td>
<td>(117)</td>
</tr>
<tr>
<td></td>
<td>Chk1</td>
<td>(118)</td>
</tr>
<tr>
<td></td>
<td>MEK1 and cyclin E1</td>
<td>(119)</td>
</tr>
<tr>
<td></td>
<td>cullin 2</td>
<td>(120)</td>
</tr>
<tr>
<td></td>
<td>NFI-A</td>
<td>(121)</td>
</tr>
<tr>
<td>miR-503</td>
<td>IGF1R and BCL2</td>
<td>(122-124)</td>
</tr>
<tr>
<td></td>
<td>Smurf2</td>
<td>(125)</td>
</tr>
<tr>
<td></td>
<td>PI3K p85 and IKK-β</td>
<td>(126)</td>
</tr>
<tr>
<td></td>
<td>FANCA</td>
<td>(127)</td>
</tr>
<tr>
<td></td>
<td>RANK</td>
<td>(128)</td>
</tr>
<tr>
<td></td>
<td>CCND1</td>
<td>(129)</td>
</tr>
<tr>
<td></td>
<td>CUGBP1</td>
<td>(130)</td>
</tr>
<tr>
<td></td>
<td>CCNE1</td>
<td>(109)</td>
</tr>
</tbody>
</table>
**Figure legends:**

**Fig. 1.** A schematic diagram showing the miRNAs that specifically affect pulmonary artery smooth muscle cells (PASMC), endothelial cells (EC), and fibroblasts, and contribute to the pathogenesis of PAH. Red (upward) arrows indicate upregulation and green (downward) arrows indicate downregulation.

**Fig. 2.** The biogenesis of miRNAs. In the nucleus, miRNA genes are transcribed into primary miRNA transcripts (pri-miRNA) by RNA polymerase II or III. Pri-miRNAs are processed into precursor miRNAs (pre-miRNAs) by the Drosha-DGCR8 complex. Pre-miRNAs are exported by exportin 5–Ran-GTP to the cytoplasm where they are processed to double-stranded mature miRNAs by Dicer and TRBP. The passenger strand is degraded, whereas the functional strand of the mature miRNA is loaded with Argonaute (Ago2) proteins and incorporated into the RNA-induced silencing complex (RISC), where the functional strand of miRNAs recognize and bind to the 3’-untranslated regions (UTR) of their mRNA targets, leading to target mRNA destabilization, mRNA degradation, and repression of protein translation.

**Fig. 3.** Molecular mechanisms involved in the role of miR-17~92 in PAH. miR-17~92 is transiently upregulated in hypoxia-induced PH, presumably by IL-6, c-Myc, or E2F1. Upregulation of miR-17~92 inhibits BMPR2 and increases pulmonary artery endothelial cell (EC) proliferation and their resistance to apoptosis. In pulmonary artery smooth muscle cells (PASMC), the role of miR-17~92 is two-fold: miR-17~92 inhibits the expression p21 to promote PASMC proliferation; miR-17~92 also inhibits PDLIM5 to induce TGF-β/SMAD signaling, inducing the expression of SMC contractile proteins.
Fig 1
Fig 2
Fig 3
References:


34


